Targeting multi-drug resistant bacteria with novel Cannabis compounds recovered directly from deep mining the genome

With bioclinical partners AMPLY located a series of novel antimicrobial peptides recovered from deep mining of the publicly available C. sativa genome.

These peptides are highly bioactive against MRSA, MDR E. coli and other key ESKAPE  pathogens. AMPLY’s use of cyclical machine learning and lab validation achieved results with low cost and project risk. 

With good biochemical handling criteria, anti-biofilm activity, varied modes of action and low-toxicity and extremely rapid kill times (< 20 minutes) they demonstrate how with only a single genome under analysis AMPLY can produce a series of viable, IP protectable, novel compounds.